Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)

PHASE3CompletedINTERVENTIONAL

Enrollment

611

Participants

Timeline

Start Date

March 7, 2014

Primary Completion Date

February 24, 2015

Study Completion Date

October 13, 2015

Conditions

Varicella

Interventions

BIOLOGICAL

VARIVAX™ New Seed Process

Varicella virus vaccine live manufactured with a new seed process

BIOLOGICAL

VARIVAX™ 2007 process

Varicella virus vaccine live manufactured with the 2007 process

BIOLOGICAL

M-M-R II™

Measles, Mumps, and Rubella virus vaccine live

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02062502 - Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) | Biotech Hunter | Biotech Hunter